{"id":349321,"date":"2025-08-25T16:54:55","date_gmt":"2025-08-25T16:54:55","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-newamsterdam-pharma-company-nv\/"},"modified":"2025-08-25T16:54:55","modified_gmt":"2025-08-25T16:54:55","slug":"how-to-buy-newamsterdam-pharma-company-nv","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","title":{"rendered":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"2025 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile NewAmsterdam Pharma Company N.V. (NAMS) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"2025 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile NewAmsterdam Pharma Company N.V. (NAMS) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Kardiyovask\u00fcler tedavide devrim yaratan ileri teknoloji biyofarmas\u00f6tik bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? NewAmsterdam Pharma (NAMS), sa\u011fl\u0131k sekt\u00f6r\u00fcndeki en heyecan verici f\u0131rsatlardan birini temsil ediyor. \u00d6nc\u00fc ila\u00e7lar\u0131 obicetrapib, klinik deneylerde ola\u011fan\u00fcst\u00fc sonu\u00e7lar g\u00f6steriyor ve d\u00fczenleyici a\u015famalar kaydediliyor; bu, potansiyel piyasa onay\u0131ndan \u00f6nce yat\u0131r\u0131m yapma \u015fans\u0131n\u0131z olabilir. Bu yat\u0131r\u0131m\u0131 yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kardiyovask\u00fcler tedavide devrim yaratan ileri teknoloji biyofarmas\u00f6tik bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? NewAmsterdam Pharma (NAMS), sa\u011fl\u0131k sekt\u00f6r\u00fcndeki en heyecan verici f\u0131rsatlardan birini temsil ediyor. \u00d6nc\u00fc ila\u00e7lar\u0131 obicetrapib, klinik deneylerde ola\u011fan\u00fcst\u00fc sonu\u00e7lar g\u00f6steriyor ve d\u00fczenleyici a\u015famalar kaydediliyor; bu, potansiyel piyasa onay\u0131ndan \u00f6nce yat\u0131r\u0131m yapma \u015fans\u0131n\u0131z olabilir. Bu yat\u0131r\u0131m\u0131 yaparken bilmeniz gereken her \u015feyi birlikte inceleyelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, NewAmsterdam Pharma Company N.V. (NAMS) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na <strong>24,32 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, Nisan 2025'teki yakla\u015f\u0131k 15 $ seviyesinden mevcut seviyelere kadar %66 civar\u0131nda etkileyici bir y\u00fckseli\u015f trendi yakalad\u0131.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin - NewAmsterdam'\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>\u015eirket haberlerine piyasa tepkilerine bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li><strong>6-7 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Beklenenden iyi sonu\u00e7lar ve azalan zararlar sonras\u0131 hisse 23,60 $'dan 24,32 $'ya (%3,0 art\u0131\u015f) y\u00fckseldi<\/li> <li><strong>30 Temmuz 2025 (Alzheimer Verileri)<\/strong>: AAIC konferans\u0131nda olumlu biyobelirte\u00e7 verileri sunulmas\u0131n\u0131n ard\u0131ndan fiyat %8 artt\u0131<\/li> <li><strong>9 Haziran 2025 (Ana Sonu\u00e7lar)<\/strong>: BROADWAY deneme ba\u015far\u0131s\u0131 duyurusunun ard\u0131ndan %12 art\u0131\u015f<\/li> <li><strong>8 May\u0131s 2025 (1. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: G\u00fc\u00e7l\u00fc nakit pozisyonu raporlamas\u0131yla m\u00fctevaz\u0131 %2 kazan\u00e7<\/li> <li><strong>Nisan 2025 (Deneme G\u00fcncellemeleri)<\/strong>: Fiyatlar\u0131n 14-17 $ aral\u0131\u011f\u0131nda dalgaland\u0131\u011f\u0131 volatil d\u00f6nem<\/li> <li><strong>Mart 2025 (D\u00fczenleyici Haz\u0131rl\u0131k)<\/strong>: EMA ba\u015fvuru haz\u0131rl\u0131klar\u0131n\u0131n ilerlemesiyle istikrarl\u0131 y\u00fckseli\u015f<\/li> <\/ul> <p>Model, klinik deneme sonu\u00e7lar\u0131 ve d\u00fczenleyici a\u015famalar\u0131n en dramatik fiyat hareketlerini yaratt\u0131\u011f\u0131n\u0131, kazan\u00e7 raporlar\u0131n\u0131n ise genellikle daha m\u00fctevaz\u0131 ancak tutarl\u0131 kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Performans Derinlemesine \u0130nceleme<\/h2> <p>NewAmsterdam'\u0131n hissesi son alt\u0131 ayda ola\u011fan\u00fcst\u00fc bir yolculuk ge\u00e7irdi:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>D\u00f6nem<\/th> <th>Fiyat Aral\u0131\u011f\u0131<\/th> <th>Temel Etkenler<\/th> <\/tr> <\/thead> <tbody> <tr> <td><strong>Mart 2025<\/strong><\/td> <td>16-18 $<\/td> <td>Erken a\u015fama deneme iyimserli\u011fi<\/td> <\/tr> <tr> <td><strong>Nisan 2025<\/strong><\/td> <td>14-17 $<\/td> <td>Piyasa volatilitesi, kar realizasyonu<\/td> <\/tr> <tr> <td><strong>May\u0131s 2025<\/strong><\/td> <td>18-21 $<\/td> <td>1. \u00e7eyrek kazan\u00e7 g\u00fcc\u00fc, nakit pozisyonu<\/td> <\/tr> <tr> <td><strong>Haziran 2025<\/strong><\/td> <td>21-24 $<\/td> <td>BROADWAY deneme ba\u015far\u0131s\u0131, yay\u0131n<\/td> <\/tr> <tr> <td><strong>Temmuz 2025<\/strong><\/td> <td>23-25 $<\/td> <td>Alzheimer verisi s\u00fcrprizi, AAIC sunumu<\/td> <\/tr> <tr> <td><strong>A\u011fustos 2025<\/strong><\/td> <td>24-26 $<\/td> <td>EMA kabul\u00fc, 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u015fma<\/td> <\/tr> <\/tbody> <\/table> <p>Hisse senedi son \u00fc\u00e7 ayda <strong>%33,70<\/strong> b\u00fcy\u00fcme ve sadece son ayda <strong>%6,59<\/strong> art\u0131\u015f g\u00f6stererek 2025'in son \u00e7eyre\u011fine g\u00fc\u00e7l\u00fc bir momentumla giriyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik ilerlemelere dayanarak, bekleyebilecekleriniz:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 35-45 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %44 ila %85 art\u0131\u015f)<\/p> <ul> <li>2025 sonlar\u0131nda potansiyel EMA onay karar\u0131 ile destekleniyor<\/li> <li>Olumlu klinik veri yay\u0131nlar\u0131n\u0131n devam\u0131<\/li> <li>G\u00fc\u00e7l\u00fc kurumsal birikim<\/li> <\/ul> <p><strong>2026 Projeksiyonu<\/strong>: Hisse ba\u015f\u0131na 50-65 $<\/p> <ul> <li>Ba\u015far\u0131l\u0131 Avrupa pazar\u0131na giri\u015f varsay\u0131m\u0131<\/li> <li>Obicetrapib sat\u0131\u015flar\u0131ndan erken gelir \u00fcretimi<\/li> <li>ABD FDA ba\u015fvuru ilerlemesi potansiyeli<\/li> <\/ul> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Hisse ba\u015f\u0131na 75-100 $<\/p> <ul> <li>Avrupa'da tam ticari faaliyet<\/li> <li>ABD pazar onay\u0131 potansiyeli<\/li> <li>Kardiyovask\u00fcler d\u0131\u015f\u0131 geni\u015fletilmi\u015f endikasyonlar<\/li> <\/ul> <p><strong>2030 Vizyonu<\/strong>: Hisse ba\u015f\u0131na 120-150+ $<\/p> <ul> <li>K\u00fcresel pazar penetrasyonu sa\u011flanm\u0131\u015f<\/li> <li>Farkl\u0131 endikasyonlardan \u00e7oklu gelir ak\u0131\u015flar\u0131<\/li> <li>B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/li> <\/ul> <p><strong>Mevcut Karar<\/strong>: G\u00dc\u00c7L\u00dc AL - K\u0131sa vadeli tetikleyiciler ve uzun vadeli b\u00fcy\u00fcme potansiyelinin birle\u015fimi, NAMS'\u0131 mevcut seviyelerde cazip bir yat\u0131r\u0131m yap\u0131yor.<\/p> <h2>\u26a0\ufe0f T\u00fcccarlar i\u00e7in Risk De\u011ferlendirmesi<\/h2> <h3>Olas\u0131 Dezavantajlar<\/h3> <ol> <li><strong>D\u00fczenleyici Risk<\/strong>: EMA veya gelecekteki FDA reddi, hisseyi %50-70 oran\u0131nda d\u00fc\u015f\u00fcrebilir<\/li> <li><strong>Klinik Geri Ad\u0131mlar<\/strong>: Devam eden denemelerde beklenmedik g\u00fcvenlik sorunlar\u0131<\/li> <li><strong>Rekabet<\/strong>: Di\u011fer CETP inhibit\u00f6rleri veya yeni lipid d\u00fc\u015f\u00fcr\u00fcc\u00fc tedaviler<\/li> <li><strong>Finansman \u0130htiya\u00e7lar\u0131<\/strong>: Ek sermaye art\u0131r\u0131mlar\u0131 gerekebilir, bu da hissedar de\u011ferini seyreltebilir<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: Biyotek hisse senetleri genellikle y\u00fcksek beta (2,0+)<\/li> <\/ol> <h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3> <ol> <li><strong>EMA Kabul\u00fc<\/strong>: Pazarlama Yetkilendirme Ba\u015fvurusu inceleme i\u00e7in kabul edildi (<a href=\"https:\/\/www.newamsterdampharma.com\">\u015eirket Duyurusu<\/a>)<\/li> <li><strong>Klinik Ba\u015far\u0131<\/strong>: Birden fazla Faz 3 denemede %35-50 LDL-C d\u00fc\u015f\u00fc\u015f\u00fc g\u00f6sterildi<\/li> <li><strong>Mali G\u00fc\u00e7<\/strong>: 783,3 milyon $ nakit pozisyonu 2026'ya kadar finansman sa\u011fl\u0131yor<\/li> <li><strong>Ortakl\u0131k De\u011feri<\/strong>: Menarini'den 833 milyon \u20ac potansiyel kilometre ta\u015f\u0131 \u00f6demeleri<\/li> <li><strong>Piyasa \u0130htiyac\u0131<\/strong>: Statin diren\u00e7li hastalarda b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7<\/li> <li><strong>Ek Uygulamalar<\/strong>: Alzheimer biyobelirte\u00e7 verileri yeni pazarlar a\u00e7\u0131yor<\/li> <\/ol> <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2'si kadar pozisyonla ba\u015flay\u0131n - biyotek volatil olabilir<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: \u00d6n\u00fcm\u00fczdeki 2-3 ay i\u00e7inde \u00f6nemli tarihler etraf\u0131nda kademeli al\u0131mlar yap\u0131n<\/li> <li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Volatilite nedeniyle %15-20 zarar durdur seviyeleri koyarak a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski koruyun<\/li> <li><strong>5 Kas\u0131m'\u0131 \u0130zleyin<\/strong>: Bir sonraki kazan\u00e7 raporu, geri \u00e7ekilme olursa daha iyi giri\u015f f\u0131rsat\u0131 sunabilir<\/li> <\/ol> <p>Esprili deneyimli tavsiyesi: \"Biyotek hisse senetleriyle ticaret yapmak fl\u00f6rt etmek gibidir - heyecan verici potansiyel ama dramatik ruh hali de\u011fi\u015fimlerine haz\u0131rl\u0131kl\u0131 olun. \u00c7ok h\u0131zl\u0131 a\u015f\u0131k olmay\u0131n ve her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!\"<\/p> <h2>\u2705 Ad\u0131m Ad\u0131m: NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"NAMS\" i\u00e7in Arama Yap\u0131n<\/td> <td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'\u0131n \u00d6ne \u00c7\u0131kma Nedenleri<\/h2> <p>Biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, yat\u0131r\u0131m yolculu\u011funuzu kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>D\u00fc\u015f\u00fck Giri\u015f Engeli<\/strong>: Sadece 5 $ minimum depozito ile \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan pozisyonunuzu olu\u015fturmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Platformun 1 dakikal\u0131k KYC s\u00fcreci sayesinde kaydolduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz<\/li> <li><strong>Esnek Para \u00c7ekme<\/strong>: 100'den fazla para \u00e7ekme y\u00f6ntemi ile kazan\u00e7lar\u0131n\u0131za kolayca eri\u015febilirsiniz<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a>, NAMS gibi karma\u015f\u0131k biyotek yat\u0131r\u0131mlar\u0131n\u0131 anlaman\u0131z i\u00e7in de\u011ferli bilgiler sunar<\/li> <\/ul> <h2>\ud83c\udfe2 \u015eirket Genel Bak\u0131\u015f\u0131: 2025'te NewAmsterdam Pharma<\/h2> <p>NewAmsterdam Pharma, statin tedavisine yeterince yan\u0131t vermeyen kardiyovask\u00fcler hastalar i\u00e7in oral CETP inhibit\u00f6r\u00fc obicetrapib geli\u015ftirmeye odaklanan ileri a\u015fama klinik biyofarmas\u00f6tik bir \u015firkettir. \u015eirket 2022'de halka a\u00e7\u0131lm\u0131\u015f ve Faz 3 klinik denemelerinde h\u0131zla ilerlemektedir.<\/p> <p><strong>G\u00fcncel Piyasa Konumu<\/strong>:<\/p> <ul> <li>Piyasa de\u011feri: ~2,75 milyar $<\/li> <li>Nakit pozisyonu: 783,3 milyon $ (2025 2. \u00e7eyrek itibar\u0131yla)<\/li> <li>\u00d6nc\u00fc \u00fcr\u00fcn: LDL-C d\u00fc\u015f\u00fcrme i\u00e7in Obicetrapib<\/li> <li>Ortakl\u0131k: Avrupa ticarile\u015ftirme i\u00e7in Menarini Grubu<\/li> <\/ul> <p><strong>2025 Y\u0131l\u0131 \u0130lgin\u00e7 Ger\u00e7e\u011fi<\/strong>: NewAmsterdam'\u0131n ara\u015ft\u0131rmalar\u0131, kardiyovask\u00fcler ilac\u0131 obicetrapib'in \"Alzheimer Hastal\u0131\u011f\u0131'n\u0131n \u00f6nemli biyobelirte\u00e7lerinde istatistiksel olarak anlaml\u0131 azalmalar\" da g\u00f6sterdi\u011fini beklenmedik \u015fekilde ortaya koydu - bu, kimsenin beklemedi\u011fi devasa yeni bir pazar\u0131n kap\u0131lar\u0131n\u0131 a\u00e7abilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, NewAmsterdam Pharma Company N.V. (NAMS) NASDAQ borsas\u0131nda hisse ba\u015f\u0131na <strong>24,32 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, Nisan 2025&#8217;teki yakla\u015f\u0131k 15 $ seviyesinden mevcut seviyelere kadar %66 civar\u0131nda etkileyici bir y\u00fckseli\u015f trendi yakalad\u0131.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131:<\/strong> Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin &#8211; NewAmsterdam&#8217;\u0131n bir sonraki \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>\u015eirket haberlerine piyasa tepkilerine bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li><strong>6-7 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Beklenenden iyi sonu\u00e7lar ve azalan zararlar sonras\u0131 hisse 23,60 $&#8217;dan 24,32 $&#8217;ya (%3,0 art\u0131\u015f) y\u00fckseldi<\/li>\n<li><strong>30 Temmuz 2025 (Alzheimer Verileri)<\/strong>: AAIC konferans\u0131nda olumlu biyobelirte\u00e7 verileri sunulmas\u0131n\u0131n ard\u0131ndan fiyat %8 artt\u0131<\/li>\n<li><strong>9 Haziran 2025 (Ana Sonu\u00e7lar)<\/strong>: BROADWAY deneme ba\u015far\u0131s\u0131 duyurusunun ard\u0131ndan %12 art\u0131\u015f<\/li>\n<li><strong>8 May\u0131s 2025 (1. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: G\u00fc\u00e7l\u00fc nakit pozisyonu raporlamas\u0131yla m\u00fctevaz\u0131 %2 kazan\u00e7<\/li>\n<li><strong>Nisan 2025 (Deneme G\u00fcncellemeleri)<\/strong>: Fiyatlar\u0131n 14-17 $ aral\u0131\u011f\u0131nda dalgaland\u0131\u011f\u0131 volatil d\u00f6nem<\/li>\n<li><strong>Mart 2025 (D\u00fczenleyici Haz\u0131rl\u0131k)<\/strong>: EMA ba\u015fvuru haz\u0131rl\u0131klar\u0131n\u0131n ilerlemesiyle istikrarl\u0131 y\u00fckseli\u015f<\/li>\n<\/ul>\n<p>Model, klinik deneme sonu\u00e7lar\u0131 ve d\u00fczenleyici a\u015famalar\u0131n en dramatik fiyat hareketlerini yaratt\u0131\u011f\u0131n\u0131, kazan\u00e7 raporlar\u0131n\u0131n ise genellikle daha m\u00fctevaz\u0131 ancak tutarl\u0131 kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Performans Derinlemesine \u0130nceleme<\/h2>\n<p>NewAmsterdam&#8217;\u0131n hissesi son alt\u0131 ayda ola\u011fan\u00fcst\u00fc bir yolculuk ge\u00e7irdi:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>D\u00f6nem<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Temel Etkenler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Mart 2025<\/strong><\/td>\n<td>16-18 $<\/td>\n<td>Erken a\u015fama deneme iyimserli\u011fi<\/td>\n<\/tr>\n<tr>\n<td><strong>Nisan 2025<\/strong><\/td>\n<td>14-17 $<\/td>\n<td>Piyasa volatilitesi, kar realizasyonu<\/td>\n<\/tr>\n<tr>\n<td><strong>May\u0131s 2025<\/strong><\/td>\n<td>18-21 $<\/td>\n<td>1. \u00e7eyrek kazan\u00e7 g\u00fcc\u00fc, nakit pozisyonu<\/td>\n<\/tr>\n<tr>\n<td><strong>Haziran 2025<\/strong><\/td>\n<td>21-24 $<\/td>\n<td>BROADWAY deneme ba\u015far\u0131s\u0131, yay\u0131n<\/td>\n<\/tr>\n<tr>\n<td><strong>Temmuz 2025<\/strong><\/td>\n<td>23-25 $<\/td>\n<td>Alzheimer verisi s\u00fcrprizi, AAIC sunumu<\/td>\n<\/tr>\n<tr>\n<td><strong>A\u011fustos 2025<\/strong><\/td>\n<td>24-26 $<\/td>\n<td>EMA kabul\u00fc, 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u015fma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse senedi son \u00fc\u00e7 ayda <strong>%33,70<\/strong> b\u00fcy\u00fcme ve sadece son ayda <strong>%6,59<\/strong> art\u0131\u015f g\u00f6stererek 2025&#8217;in son \u00e7eyre\u011fine g\u00fc\u00e7l\u00fc bir momentumla giriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik ilerlemelere dayanarak, bekleyebilecekleriniz:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 35-45 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %44 ila %85 art\u0131\u015f)<\/p>\n<ul>\n<li>2025 sonlar\u0131nda potansiyel EMA onay karar\u0131 ile destekleniyor<\/li>\n<li>Olumlu klinik veri yay\u0131nlar\u0131n\u0131n devam\u0131<\/li>\n<li>G\u00fc\u00e7l\u00fc kurumsal birikim<\/li>\n<\/ul>\n<p><strong>2026 Projeksiyonu<\/strong>: Hisse ba\u015f\u0131na 50-65 $<\/p>\n<ul>\n<li>Ba\u015far\u0131l\u0131 Avrupa pazar\u0131na giri\u015f varsay\u0131m\u0131<\/li>\n<li>Obicetrapib sat\u0131\u015flar\u0131ndan erken gelir \u00fcretimi<\/li>\n<li>ABD FDA ba\u015fvuru ilerlemesi potansiyeli<\/li>\n<\/ul>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Hisse ba\u015f\u0131na 75-100 $<\/p>\n<ul>\n<li>Avrupa&#8217;da tam ticari faaliyet<\/li>\n<li>ABD pazar onay\u0131 potansiyeli<\/li>\n<li>Kardiyovask\u00fcler d\u0131\u015f\u0131 geni\u015fletilmi\u015f endikasyonlar<\/li>\n<\/ul>\n<p><strong>2030 Vizyonu<\/strong>: Hisse ba\u015f\u0131na 120-150+ $<\/p>\n<ul>\n<li>K\u00fcresel pazar penetrasyonu sa\u011flanm\u0131\u015f<\/li>\n<li>Farkl\u0131 endikasyonlardan \u00e7oklu gelir ak\u0131\u015flar\u0131<\/li>\n<li>B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/li>\n<\/ul>\n<p><strong>Mevcut Karar<\/strong>: G\u00dc\u00c7L\u00dc AL &#8211; K\u0131sa vadeli tetikleyiciler ve uzun vadeli b\u00fcy\u00fcme potansiyelinin birle\u015fimi, NAMS&#8217;\u0131 mevcut seviyelerde cazip bir yat\u0131r\u0131m yap\u0131yor.<\/p>\n<h2>\u26a0\ufe0f T\u00fcccarlar i\u00e7in Risk De\u011ferlendirmesi<\/h2>\n<h3>Olas\u0131 Dezavantajlar<\/h3>\n<ol>\n<li><strong>D\u00fczenleyici Risk<\/strong>: EMA veya gelecekteki FDA reddi, hisseyi %50-70 oran\u0131nda d\u00fc\u015f\u00fcrebilir<\/li>\n<li><strong>Klinik Geri Ad\u0131mlar<\/strong>: Devam eden denemelerde beklenmedik g\u00fcvenlik sorunlar\u0131<\/li>\n<li><strong>Rekabet<\/strong>: Di\u011fer CETP inhibit\u00f6rleri veya yeni lipid d\u00fc\u015f\u00fcr\u00fcc\u00fc tedaviler<\/li>\n<li><strong>Finansman \u0130htiya\u00e7lar\u0131<\/strong>: Ek sermaye art\u0131r\u0131mlar\u0131 gerekebilir, bu da hissedar de\u011ferini seyreltebilir<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: Biyotek hisse senetleri genellikle y\u00fcksek beta (2,0+)<\/li>\n<\/ol>\n<h3>2025 \u0130\u00e7in Olumlu Sinyaller<\/h3>\n<ol>\n<li><strong>EMA Kabul\u00fc<\/strong>: Pazarlama Yetkilendirme Ba\u015fvurusu inceleme i\u00e7in kabul edildi (<a href=\"https:\/\/www.newamsterdampharma.com\">\u015eirket Duyurusu<\/a>)<\/li>\n<li><strong>Klinik Ba\u015far\u0131<\/strong>: Birden fazla Faz 3 denemede %35-50 LDL-C d\u00fc\u015f\u00fc\u015f\u00fc g\u00f6sterildi<\/li>\n<li><strong>Mali G\u00fc\u00e7<\/strong>: 783,3 milyon $ nakit pozisyonu 2026&#8217;ya kadar finansman sa\u011fl\u0131yor<\/li>\n<li><strong>Ortakl\u0131k De\u011feri<\/strong>: Menarini&#8217;den 833 milyon \u20ac potansiyel kilometre ta\u015f\u0131 \u00f6demeleri<\/li>\n<li><strong>Piyasa \u0130htiyac\u0131<\/strong>: Statin diren\u00e7li hastalarda b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7<\/li>\n<li><strong>Ek Uygulamalar<\/strong>: Alzheimer biyobelirte\u00e7 verileri yeni pazarlar a\u00e7\u0131yor<\/li>\n<\/ol>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2&#8217;si kadar pozisyonla ba\u015flay\u0131n &#8211; biyotek volatil olabilir<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: \u00d6n\u00fcm\u00fczdeki 2-3 ay i\u00e7inde \u00f6nemli tarihler etraf\u0131nda kademeli al\u0131mlar yap\u0131n<\/li>\n<li><strong>Zarar Durdur Seviyeleri Belirleyin<\/strong>: Volatilite nedeniyle %15-20 zarar durdur seviyeleri koyarak a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski koruyun<\/li>\n<li><strong>5 Kas\u0131m&#8217;\u0131 \u0130zleyin<\/strong>: Bir sonraki kazan\u00e7 raporu, geri \u00e7ekilme olursa daha iyi giri\u015f f\u0131rsat\u0131 sunabilir<\/li>\n<\/ol>\n<p>Esprili deneyimli tavsiyesi: &#8220;Biyotek hisse senetleriyle ticaret yapmak fl\u00f6rt etmek gibidir &#8211; heyecan verici potansiyel ama dramatik ruh hali de\u011fi\u015fimlerine haz\u0131rl\u0131kl\u0131 olun. \u00c7ok h\u0131zl\u0131 a\u015f\u0131k olmay\u0131n ve her zaman bir \u00e7\u0131k\u0131\u015f stratejiniz olsun!&#8221;<\/p>\n<h2>\u2705 Ad\u0131m Ad\u0131m: NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;NAMS&#8221; i\u00e7in Arama Yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;\u0131n \u00d6ne \u00c7\u0131kma Nedenleri<\/h2>\n<p>Biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, yat\u0131r\u0131m yolculu\u011funuzu kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>D\u00fc\u015f\u00fck Giri\u015f Engeli<\/strong>: Sadece 5 $ minimum depozito ile \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan pozisyonunuzu olu\u015fturmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Platformun 1 dakikal\u0131k KYC s\u00fcreci sayesinde kaydolduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>Esnek Para \u00c7ekme<\/strong>: 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi ile kazan\u00e7lar\u0131n\u0131za kolayca eri\u015febilirsiniz<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a>, NAMS gibi karma\u015f\u0131k biyotek yat\u0131r\u0131mlar\u0131n\u0131 anlaman\u0131z i\u00e7in de\u011ferli bilgiler sunar<\/li>\n<\/ul>\n<h2>\ud83c\udfe2 \u015eirket Genel Bak\u0131\u015f\u0131: 2025&#8217;te NewAmsterdam Pharma<\/h2>\n<p>NewAmsterdam Pharma, statin tedavisine yeterince yan\u0131t vermeyen kardiyovask\u00fcler hastalar i\u00e7in oral CETP inhibit\u00f6r\u00fc obicetrapib geli\u015ftirmeye odaklanan ileri a\u015fama klinik biyofarmas\u00f6tik bir \u015firkettir. \u015eirket 2022&#8217;de halka a\u00e7\u0131lm\u0131\u015f ve Faz 3 klinik denemelerinde h\u0131zla ilerlemektedir.<\/p>\n<p><strong>G\u00fcncel Piyasa Konumu<\/strong>:<\/p>\n<ul>\n<li>Piyasa de\u011feri: ~2,75 milyar $<\/li>\n<li>Nakit pozisyonu: 783,3 milyon $ (2025 2. \u00e7eyrek itibar\u0131yla)<\/li>\n<li>\u00d6nc\u00fc \u00fcr\u00fcn: LDL-C d\u00fc\u015f\u00fcrme i\u00e7in Obicetrapib<\/li>\n<li>Ortakl\u0131k: Avrupa ticarile\u015ftirme i\u00e7in Menarini Grubu<\/li>\n<\/ul>\n<p><strong>2025 Y\u0131l\u0131 \u0130lgin\u00e7 Ger\u00e7e\u011fi<\/strong>: NewAmsterdam&#8217;\u0131n ara\u015ft\u0131rmalar\u0131, kardiyovask\u00fcler ilac\u0131 obicetrapib&#8217;in &#8220;Alzheimer Hastal\u0131\u011f\u0131&#8217;n\u0131n \u00f6nemli biyobelirte\u00e7lerinde istatistiksel olarak anlaml\u0131 azalmalar&#8221; da g\u00f6sterdi\u011fini beklenmedik \u015fekilde ortaya koydu &#8211; bu, kimsenin beklemedi\u011fi devasa yeni bir pazar\u0131n kap\u0131lar\u0131n\u0131 a\u00e7abilir!<\/p>\n"},"faq":[{"question":"NewAmsterdam Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"NAMS\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"NewAmsterdam Pharma'n\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"Ana \u00fcr\u00fcnleri, kardiyovask\u00fcler hastalar i\u00e7in LDL-C d\u00fc\u015f\u00fcrmeye y\u00f6nelik oral CETP inhibit\u00f6r\u00fc olan obicetrapib'tir."},{"question":"NewAmsterdam Pharma'n\u0131n 2025 sonu fiyat hedefi nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat hedefi 35-45 $ aral\u0131\u011f\u0131nda olup, mevcut seviyelerden %44 ila %85 art\u0131\u015f \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"D\u00fczenleyici riskler, klinik deneme sorunlar\u0131, rekabet, ek finansman ihtiya\u00e7lar\u0131 ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyeleri nelerdir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, ortalama maliyetle al\u0131m yap\u0131n, zarar durdur seviyeleri belirleyin ve \u00f6nemli tarihleri takip edin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"NewAmsterdam Pharma hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"NAMS\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak sipari\u015f verin ve i\u015flemi onaylay\u0131n."},{"question":"NewAmsterdam Pharma'n\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"Ana \u00fcr\u00fcnleri, kardiyovask\u00fcler hastalar i\u00e7in LDL-C d\u00fc\u015f\u00fcrmeye y\u00f6nelik oral CETP inhibit\u00f6r\u00fc olan obicetrapib'tir."},{"question":"NewAmsterdam Pharma'n\u0131n 2025 sonu fiyat hedefi nedir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat hedefi 35-45 $ aral\u0131\u011f\u0131nda olup, mevcut seviyelerden %44 ila %85 art\u0131\u015f \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131d\u0131r?","answer":"D\u00fczenleyici riskler, klinik deneme sorunlar\u0131, rekabet, ek finansman ihtiya\u00e7lar\u0131 ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m tavsiyeleri nelerdir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, ortalama maliyetle al\u0131m yap\u0131n, zarar durdur seviyeleri belirleyin ve \u00f6nemli tarihleri takip edin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T16:54:55+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T16:54:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"},\"wordCount\":25,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\",\"name\":\"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-25T16:54:55+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","og_locale":"tr_TR","og_type":"article","og_title":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T16:54:55+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T16:54:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"wordCount":25,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/","name":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r - NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-25T16:54:55+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma Company N.V. (NAMS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; NewAmsterdam Pharma Company N.V. (NAMS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":349316,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu NewAmsterdam Pharma Company N.V. (NAMS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"},"pt_AA":{"locale":"pt_AA","id":349313,"slug":"how-to-buy-newamsterdam-pharma-company-nv","post_title":"Como comprar a\u00e7\u00f5es da NewAmsterdam Pharma Company N.V. (NAMS) - Investimento em a\u00e7\u00f5es da NewAmsterdam Pharma Company N.V. (NAMS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-newamsterdam-pharma-company-nv\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=349321"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349321\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=349321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=349321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=349321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}